Cargando…

HLAII peptide presentation of infliximab increases when complexed with TNF

CD4+ T-cell activation through recognition of Human Leukocyte Antigen II (HLAII)-presented peptides is a key step in the development of unwanted immune response against biotherapeutics, such as the generation of anti-drug antibodies (ADA). Therefore, the identification of HLAII-presented peptides de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casasola-LaMacchia, Andrea, Seward, Robert Joseph, Tourdot, Sophie, Willetts, Matthew, Kruppa, Gary, Agostino, Michael J., Bergeron, Gabrielle, Ahyi-Amendah, Nathalie, Ciarla, Andrew, Lu, Zhaojiang, Kim, Hai-Young, Hickling, Timothy P., Neubert, Hendrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513746/ https://www.ncbi.nlm.nih.gov/pubmed/36177046 http://dx.doi.org/10.3389/fimmu.2022.932252

Ejemplares similares

Human leukocyte antigen class II quantification by targeted mass spectrometry in dendritic-like cell lines and monocyte-derived dendritic cells
por: Casasola-LaMacchia, A., et al.
Publicado: (2021)

Natural variation of ncHLAII molecules: challenges and perspectives
por: Álvaro-Benito, Miguel
Publicado: (2022)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab
por: Dénarié, Delphine, et al.
Publicado: (2017)

Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease
por: Amini Kadijani, Azade, et al.
Publicado: (2017)

Circulating bioactive TNF in rheumatoid arthritis patients treated with infliximab: link to clinical response
por: Marotte, H, et al.
Publicado: (2003)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn’s Disease
por: Ye, Chenglin, et al.
Publicado: (2022)

Erratum: Transmembrane TNF-α Density, But Not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease
por: Amini Kadijani, Azade, et al.
Publicado: (2017)

Polymorphism at the position -308 of TNF-α gene influences outcome of infliximab therapy in rheumatoid arthritis
por: Mugnier, B, et al.
Publicado: (2004)

Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease
por: Kamel, Amir Y., et al.
Publicado: (2016)

Ulcerative Colitis-associated Spondyloarthritis Successfully Treated with Infliximab in the Absence of Enhanced TNF-α Responses
por: Fujita, Shunsuke, et al.
Publicado: (2022)

The Anti-TNF-α Antibody Infliximab Inhibits the Expression of Fat-Transporter-Protein FAT/CD36 in a Selective Hepatic-Radiation Mouse Model
por: Martius, Gesa, et al.
Publicado: (2015)

Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab
por: Chimenti, Maria Sole, et al.
Publicado: (2013)

Infliximab Reverses Suppression of Cholesterol Efflux Proteins by TNF-α: A Possible Mechanism for Modulation of Atherogenesis
por: Voloshyna, Iryna, et al.
Publicado: (2014)

Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease
por: Steenholdt, Casper, et al.
Publicado: (2016)

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis
por: Liu, Jing, et al.
Publicado: (2016)

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar
por: Buurman, D. J., et al.
Publicado: (2018)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
por: Kaniewska, Magdalena, et al.
Publicado: (2020)

Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn's Disease
por: Fonseca, Ashley, et al.
Publicado: (2021)

Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review
por: Chen, Jiaying, et al.
Publicado: (2023)

Anti‐TNFα induced lupus due to infliximab therapy in a patient with concurrent Crohn's disease
por: Sharma, Akanksha, et al.
Publicado: (2023)

Glycogen Fuels Survival During Hyposmotic-Anoxic Stress in Caenorhabditis elegans
por: LaMacchia, John C., et al.
Publicado: (2015)

Plasma leptin and neuropeptide Y concentrations in patients with rheumatoid arthritis treated with infliximab, a TNF-α antagonist
por: Kopec-Medrek, Magdalena, et al.
Publicado: (2011)

Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results
por: Süha, Çetin, et al.
Publicado: (2014)

Disseminated tuberculosis infection and paradoxical reaction during antimycobacterial treatment related to TNF-alpha blocker agent Infliximab
por: Unlu, Mehmet, et al.
Publicado: (2014)

Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab
por: Blais, Anne, et al.
Publicado: (2023)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
por: Ducourau, Emilie, et al.
Publicado: (2011)

Infliximab and Dexamethasone Attenuate the Ductular Reaction in Mice
por: Verhulst, Stefaan, et al.
Publicado: (2016)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

The Effects of Infliximab on Laminin, NFκB, and Anti-TNF Expression through Its Effect on Ischemic Liver Tissue
por: Akdogan, Remzi Adnan, et al.
Publicado: (2016)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab
por: Gorovits, B., et al.
Publicado: (2018)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
por: Peng, Kuan, et al.
Publicado: (2023)

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
por: Petit, Juliette, et al.
Publicado: (2021)

Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

A case study: consequences of ANTI-TNFα therapy and foot ulcerations. A patient with Ankylosing Spondylitis (AS) treated with Infliximab
por: Edgson, Lucy, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ls99ej7egq2crfjcn4nlg8p0co